Latest News and Press Releases

New York, USA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Rare Skin Disorders Market: Key Insights into Future Outlook and Trends of Pemphigus Vulgaris, Epidermolysis Bullosa, Palmoplantar Pustulosis, and...

HAMILTON, Bermuda, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate...

HAMILTON, Bermuda, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate...

- Statistically significant primary efficacy endpoint of reduction in weekly-average Worst-Itch Numeric Rating Scale (WI-NRS) at Week 8 -- Statistically significant secondary efficacy endpoint of...

NEW HAVEN, Conn., April 08, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of...

NEW HAVEN, Conn., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER...

Advancement of Nalbuphine ER in Clinical Development for Three Indications Cash Position of $63.5 Million Expected to Fund Operations Through At Least Q1 2021 NEW HAVEN, Conn., Nov. 14, 2019 ...

NEW HAVEN, Conn., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...

NEW HAVEN, Conn., June 18, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...

HAMILTON, Bermuda, May 13, 2019 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...